- Home
- ZJYL vs OTLK Comparison
ZJYL vs OTLK Comparison
Compare ZJYL & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZJYL | OTLK |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.5M | 42.8M |
| IPO Year | 2023 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ZJYL | OTLK |
|---|---|---|
| Price | $0.24 | $2.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.25 |
| AVG Volume (30 Days) | 332.8K | ★ 5.5M |
| Earning Date | 08-20-2025 | 12-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $22,826,624.00 | $1,505,322.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $342.80 |
| P/E Ratio | $20.76 | ★ N/A |
| Revenue Growth | ★ 13.42 | N/A |
| 52 Week Low | $0.22 | $0.79 |
| 52 Week High | $1.42 | $3.39 |
Technical Indicators
Market Signals| Indicator | ZJYL | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 33.58 | 69.44 |
| Support Level | $0.23 | $1.51 |
| Resistance Level | $0.28 | $2.10 |
| Average True Range (ATR) | 0.02 | 0.20 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 13.81 | 93.22 |
Price Performance
Historical ComparisonAbout ZJYL JIN MEDICAL INTERNATIONAL LTD.
Jin Medical International Ltd offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other living aids products to be used by people with disabilities or impaired mobility. The company's products are sold to distributors in both China and overseas markets. Its product offerings comprise Wheelechaire serirs, Bath products, oxygen machines, and nursing products. Geographically, it generates the majority of its revenue from Japan.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.